Navigation Links
Publication of Supplementary Prospectus
Date:4/29/2008

BASINGSTOKE, England and PHILADELPHIA, April 29 /PRNewswire-FirstCall/ -- Shire plc ("Shire") (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces that following the publication of the Prospectus by Shire Limited on 16 April 2008 in relation to the introduction of up to 700,000,000 Ordinary Shares of 5 pence each to the Official List, a Supplementary Prospectus is to be made available through publication on Shire's website: http://www.shire.com for the purpose of disclosing Shire's:

- US Food and Drug Administration approval of VYVANSE's (lisdexamfetamine dimesylate) supplementary New Drug Application for use in the treatment of Attention Deficit Hyperactivity Disorder in adults, which was announced by Shire on 23 April 2008;

- acquisition of arylsufatase-A from Zymenex A/S, which was announced by Shire on 24 April 2008. Arylsufatase-A, currently called METAZYM(TM), is an enzyme replacement therapy in Phase 1-2 clinical trials and being investigated for the treatment of Metachromatic Leukodystrophy; and

- unaudited financial results for the quarter ended 31 March 2008, which were announced by Shire on 25 April 2008.

The Supplementary Prospectus has been approved by the UK Listing Authority (the "UKLA"). Copies of the Supplementary Prospectus have been submitted to the UKLA and are available for inspection at the UKLA's Document Viewing Facility, which is situated at the Financial Services Authority, 25 The North Colonnade, Canary Wharf, London E14 5HS.

Copies of the Supplementary Prospectus will also be available for inspection during usual business hours on Monday to Friday of each week (public holidays excepted) from the date of publication until admission (expected to be at 8.00 a.m. (London time) on 23 May 2008) at the registered office of Shire Limited being 22 Grenville Street, St. Helier, Jersey, JE4 8PX and at the offices of Slaughter an
'/>"/>

SOURCE Shire PLC
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Oncolytics Biotech Inc. Announces Journal of Immunology Publication on Reovirus Activation of Dendritic Cells
2. Oncolytics Biotech Inc. Announces Gene Therapy Publication on Reovirus Treatment for Melanoma
3. United BioSource Acquires Leading Publication Planning Software and Services Company
4. Publication Addresses Misconceptions About Emergency Contraception
5. Oncolytics Biotech Inc. Announces Publication of Research on Immune Response to REOLYSIN(R) during a Phase I Clinical Trial
6. Publication in Clinical Cancer Research Confirms Ability of Peregrines Bavituximab to Target Tumor Blood Vessels with Excellent Specificity
7. Ortho Biotech Statement On JAMA Publication Regarding Erythropoiesis-Stimulating Agents
8. Oncolytics Biotech Inc. Announces Publication of Research on Combination Reovirus and Radiation Therapy
9. BioTrends Releases Fourth Annual Nephrology TreatmentTrends Publication Highlighting Market Trends for Renal Anemia, Hyperphosphatemia, and Secondary Hyperparathyroidism
10. Oncolytics Biotech Inc. Announces Publication of Research on Combination Reovirus and Cyclophosphamide Treatment
11. Research by Case Western Reserve University, VA earns cover of prestigious science publication
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/12/2014)... Albany, New York (PRWEB) July 12, 2014 ... market analysis for various reagents used in ... biotechnology is driving the life science reagents ... this study include manufacturers and providers of ... Science Reagents Market Report: http://www.transparencymarketresearch.com/life-sciences-reagents-analytical-reagents.html . ...
(Date:7/11/2014)... , July 11, 2014 , Not ... in, into or from any jurisdiction where to do so ... jurisdiction.  Shire plc ("Shire" or the "Company") (LSE: ... this afternoon.  Shire confirms it has held a meeting with ... by Shire without the prior agreement or approval of AbbVie. ...
(Date:7/11/2014)... 11, 2014 BCC Research ( http://www.bccresearch.com ... POLYMERASE CHAIN REACTION (PCR) TECHNOLOGY: GLOBAL MARKETS , the ... reached nearly $140 billion in 2013. This is estimated ... five-year compound annual growth rate (CAGR) of 28.6%. , ... interesting and exciting possibilities within the broader PCR field. ...
(Date:7/11/2014)... - Sunovion Pharmaceuticals Canada Inc. (Sunovion) today announced that ... use as a once-daily adjunctive therapy for the treatment ... not satisfactorily controlled with conventional therapy.  APTIOM TM ... years of age. Epilepsy is one ... Epilepsy Canada, it affects 0.6% of the population and ...
Breaking Biology Technology:Transparency Market Research: Life Science Reagents Market- PCR Reagent Kits, Cell and Tissue Culture, Flow Cytometry, Electrophoresis and Chromatography 2Transparency Market Research: Life Science Reagents Market- PCR Reagent Kits, Cell and Tissue Culture, Flow Cytometry, Electrophoresis and Chromatography 3Shire plc - Statement re: Media Speculation 2Global Market for Digital Polymerase Chain Reaction Technology to Reach $490 Billion by 2018; Equipment Sector Accounts for the Fastest Growing Segment With 33% CAGR 2Global Market for Digital Polymerase Chain Reaction Technology to Reach $490 Billion by 2018; Equipment Sector Accounts for the Fastest Growing Segment With 33% CAGR 3Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 2Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 3Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 4
... 2 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ... has been completed in the Phase II component of ... paclitaxel/carboplatin for patients with advanced cancers. The principal investigators ... Institute of Cancer Research, London, England, and Dr. Geoff ...
... statistical analysis technique that identifies and removes systematic ... could lead to more precise and reliable measurement ... industrial applications. Known as sequential profile adjustment ... the amount of experimental data required to make ...
... SHANGHAI, July 1 /PRNewswire-Asia/ -- WuXi PharmaTech ... had received an award from BASF for,excellent service and outstanding ... ingredients. , (Logo: http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO ... for a good CRO collaboration partner for years, and,today I ...
Cached Biology Technology:Oncolytics Biotech(R) Inc. Completes Patient Enrolment in U.K. Combination REOLYSIN(R) and Paclitaxel/Carboplatin Head and Neck Cancer Trial 2New statistical technique improves precision of nanotechnology data 2New statistical technique improves precision of nanotechnology data 3New statistical technique improves precision of nanotechnology data 4WuXi PharmaTech Receives Award from BASF 2
(Date:7/10/2014)... in New Mexico, nearly every public golf course is ... potable water supplies. Across the U.S. Southwest as a ... treated effluent. Reusing the effluent increases the sustainability of ... alike fertilize their lawns during the growing season. The ... State University turfgrass expert has a new vision for ...
(Date:7/10/2014)... NEW YORK , June 27, 2014 /PRNewswire/ ... against Provectus Biopharmaceuticals, Inc. ("Provectus" or the "Company")(NYSE-MKT: ... action, filed in United States District Court, Middle ... Division, is on behalf of a class consisting ... otherwise acquired Provectus securities between December 17, 2013 ...
(Date:7/10/2014)... CORAL SPRINGS, Florida , July 1, 2014 ... smart wallets pave way for convenience and improved security: NXT-ID, ... Google Inc. (NASDAQ: GOOG ), Apple Inc. (NASDAQ: ... ) and MasterCard Corporation (NYSE: MA) NXT-ID, Inc., (OTCQB: ... market, is pleased to announce that the second series of ...
Breaking Biology News(10 mins):'Tailored' water -- the latest in lawn care 2SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Provectus Biopharmaceuticals, Inc. and Certain Officers - PVCT 2SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Provectus Biopharmaceuticals, Inc. and Certain Officers - PVCT 3Advantages for Digital Wallets Eliminate Need to Carry Credit Cards - Large Scale CNBC Ad Campaign for Latest Smart Wallet to Commence July 7th 2Advantages for Digital Wallets Eliminate Need to Carry Credit Cards - Large Scale CNBC Ad Campaign for Latest Smart Wallet to Commence July 7th 3Advantages for Digital Wallets Eliminate Need to Carry Credit Cards - Large Scale CNBC Ad Campaign for Latest Smart Wallet to Commence July 7th 4Advantages for Digital Wallets Eliminate Need to Carry Credit Cards - Large Scale CNBC Ad Campaign for Latest Smart Wallet to Commence July 7th 5
... of the Alps, the Andes and the Himalayas in size ... hidden under the world,s oceans. Now in a special issue ... life on these submerged mountain ranges and reveal why these ... bathymetry of our oceans is now resolved at a scale ...
... ARBOR, Mich. -- Physician,s confidence in their abilities to counsel ... to their own personal habits, according to a study by ... depended on a doctor,s own exercise time, being overweight, and ... about diet and exercise. The study, published online ahead ...
... at Huntsman Cancer Institute (HCI) at the University of Utah ... maintenance and repair of the cell,s cytoskeleton, or internal framework, ... The research has implications for cancer, as well as other ... disease. The research was published in the Sep. 14, 2010, ...
Cached Biology News:Marine scientists unveil the mystery of life on undersea mountains 2Doctor's health habits affect patient counseling 2Study offers first explanation of how cells rapidly repair and maintain structure 2
...
Mouse polyclonal antibody to PRDM2 - PR domain containing 2, with ZNF domain...
Anti Human S14G-Humanin Polyclonal Antibody...
... LABTrack provides a familiar interface for ... and warehousing. The transition from paper ... transparent. LABTrack contains an integrated ... and rules mechanism. These functions allow ...
Biology Products: